Menu
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Real-World Evidence Conference
Opening Remarks and Session 1: Year in Review
Session Chair(s)
Simon Dagenais, PhD, MSc
- Senior Director, Real-World Evidence
- Pfizer Inc, United States
This session is intended to provide an overview of recent events related to RWE in the past year, including regulatory decisions, guidance, and projects, as well as publications, guidelines, and industry activities. The session will choose a few key examples for discussion, provide a brief description of each event, place the event in a historical context to highlight what is new, and attempt op highlight key themes that may emerge in the future related to these events. This session may provide some background for other sessions that will delve into these events and themes in more depth.
Learning Objective : At the conclusion of this session, participants should be able to:
- Describe recent events related to RWE in the past year
- Discuss why these recent events are important to RWE
- Identify new events in context of existing information on the topic
Speaker(s)
FDA Guidance related to RWE
John Concato, MD, MPH, MS
- Associate Director for Real-World Evidence Analytics, OMP, CDER
- FDA, United States
Recent Examples of RWE Submissions
Nirosha Lederer, PhD, MS
- Director, Real-World Evidence Strategy
- Aetion, United States
Update on RWE Reporting Quality
Shirley Wang, PhD, MSc, FISPE
- Assistant Professor of Medicine
- Harvard Medical School, United States
Update on RCT DUPLICATE Project
Jessica Franklin, PhD
- Principal Consultant, Epidemiology and Real-World Evidence
- Optum, United States
Financial Trends in the RWE Industry
Dan Gebremedhin, MD, MBA
- Partner
- Flare Capital Partners, United States
Contact us
Registration Questions?
Preconference Short Courses
Additional Information
Sign up to be notified when registration opens for the DIA 2022 Events
Real-World Evidence Conference Resource Kit